RxDoctor Payments Data

Nimisha Mehta, MD

Internal Medicine · Lewisville, TXNPI 1699783696

Payments from drug & device makers

$515in general payments, 2019–2025

Across 20 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$150
  • Novo Nordisk$99
  • Lilly USA, LLC$95
  • Otsuka America Pharmaceutical, Inc.$68
  • AstraZeneca$38
  • Novartis$27
  • plus $39 from 3 others

What the payments were for

  • Speaking & faculty fees$15029%
  • Food & beverage$36571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$515 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,999
Medicare patients
118
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$52,499
OzempicSemaglutide42$51,357
JanuviaSitagliptin Phosphate32$40,670
JardianceEmpagliflozin25$29,459
FarxigaDapagliflozin Propanediol26$19,580
JanumetSitagliptin Phos/Metformin Hcl17$18,748
EntrestoSacubitril/Valsartan18$16,007
XareltoRivaroxaban16$12,368
MyrbetriqMirabegron18$11,418
SavaysaEdoxaban Tosylate12$5,159
Breo ElliptaFluticasone/Vilanterol12$5,073
Levothyroxine Sodium375$3,236
Atorvastatin Calcium326$3,002
Rosuvastatin Calcium158$2,256
Memantine Hcl90$2,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$11$59,41749 claims
PfizerEliquis, Paxlovid$12$53,92995 claims
Novo NordiskOzempic$99$51,35742 claims
AstraZenecaFarxiga$38$19,58026 claims
NovartisEntresto$27$16,00718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →